Progenics Pharmaceuticals (PGNX) Upgraded at BidaskClub

BidaskClub upgraded shares of Progenics Pharmaceuticals (NASDAQ:PGNX) from a sell rating to a hold rating in a research note published on Wednesday.

Other analysts also recently issued reports about the company. Cantor Fitzgerald reaffirmed a buy rating and set a $15.00 price objective on shares of Progenics Pharmaceuticals in a research note on Wednesday, January 17th. ValuEngine raised Progenics Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, December 7th. Finally, Zacks Investment Research downgraded Progenics Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, January 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $12.35.

Shares of Progenics Pharmaceuticals (NASDAQ PGNX) opened at $5.97 on Wednesday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.86 and a current ratio of 7.86. The company has a market capitalization of $406.86, a P/E ratio of -7.56 and a beta of 3.41. Progenics Pharmaceuticals has a one year low of $4.60 and a one year high of $11.72.

A number of institutional investors and hedge funds have recently bought and sold shares of PGNX. BlackRock Inc. raised its stake in shares of Progenics Pharmaceuticals by 2.1% during the 4th quarter. BlackRock Inc. now owns 9,996,741 shares of the biotechnology company’s stock worth $59,482,000 after buying an additional 202,932 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Progenics Pharmaceuticals by 4.1% during the 2nd quarter. Vanguard Group Inc. now owns 4,300,478 shares of the biotechnology company’s stock worth $29,200,000 after buying an additional 167,708 shares in the last quarter. Eagle Asset Management Inc. raised its stake in shares of Progenics Pharmaceuticals by 3.9% during the 3rd quarter. Eagle Asset Management Inc. now owns 4,166,919 shares of the biotechnology company’s stock worth $32,210,000 after buying an additional 154,553 shares in the last quarter. State Street Corp raised its stake in shares of Progenics Pharmaceuticals by 42.7% during the 2nd quarter. State Street Corp now owns 3,708,788 shares of the biotechnology company’s stock worth $25,186,000 after buying an additional 1,110,067 shares in the last quarter. Finally, Carillon Tower Advisers Inc. purchased a new position in shares of Progenics Pharmaceuticals during the 4th quarter worth approximately $21,790,000. 84.53% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Progenics Pharmaceuticals (PGNX) Upgraded at BidaskClub” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2018/02/17/progenics-pharmaceuticals-pgnx-upgraded-at-bidaskclub.html.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply